Vitamin D and lung cancer

Expert Review of Respiratory Medicine

Volumn 5, Issue 3, 2011, Pages 305-309

  Ramnath, Nithya ^a,b   Kim, SoHee ^a   Christensen, Paul J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CYP24A1; lung cancer; vitamin D

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITRIOL; CYP24A1 ENZYME; CYP27B1 ENZYME; CYTOCHROME P450; OXYGENASE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

CANCER CELL; CLINICAL TRIAL; CYPERACEAE; DRUG EFFECT; DRUG MECHANISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MORTALITY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; VITAMIN SUPPLEMENTATION;

EID: 79959738378     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.31     Document Type: Review

References (40)

1. Zhou W, Heist RS, Liu G et al. Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol. Biomarkers Prev. 14(10), 2303-2309 (2005 (Pubitemid 41437829)
2. Zhou W, Heist RS, Liu G et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J. Clin. Oncol. 25(5), 479-485 (2007 (Pubitemid 350002952)
3. Rassnick KM, Muindi JR, Johnson CS et al. In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. Cancer Chemother. Pharmacol. 62(5), 881-891 (2008
4. Zhu K, Bruce D, Austin N et al. Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. J. Bone Miner. Res. 23(8), 1343-1348 (2008 (Pubitemid 352040190)
5. Beer TM, Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol. Cancer Ther. 3(3), 373-381 (2004 (Pubitemid 39193713)
6. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br. J. Nutr. 89(5), 552-572 (2003 (Pubitemid 36592083)
7. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am. J. Clin. Nutr. 80(Suppl. 6), 1689S-1696S (2004
8. Shaffer PL, Gewirth DT. Structural basis of VDR-DNA interactions on direct repeat response elements. EMBO J. 21(9), 2242-2252 (2002 (Pubitemid 34516783)
9. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev. 26(5), 662-687 (2005 (Pubitemid 41127276)
10. Chapuy MC, Preziosi P, Maamer M et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 7(5), 439-443 (1997 (Pubitemid 27443069)
11. Uitterlinden AG, Fang Y, Van Meurs JB et al. Genetics and biology of vitamin D receptor polymorphisms. Gene 338(2), 143-156 (2004 (Pubitemid 39094759)
12. Bouillon R, Verlinden L, Eelen G et al. Mechanisms for the selective action of Vitamin D analogs. J. Steroid Biochem. Mol. Biol. 97(1-2), 21-30 (2005 (Pubitemid 41546210)
13. Holick MF. Vitamin D deficiency. N. Engl. J. Med. 357(3), 266-281 (2007
14. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 7(9), 684-700 (2007 (Pubitemid 47327412)
15. Eelen G, Verlinden L, van Camp M et al. The effects of 1a,25-dihydroxyvitamin D3 on the expression of DNA replication genes. J. Bone Miner. Res. 19(1), 133-146 (2004 (Pubitemid 41295146)
16. Wang QM, Jones JB, Studzinski GP. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res. 56(2), 264-267 (1996 (Pubitemid 26026352)
17. McGuire TF, Trump DL, Johnson CS. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J. Biol. Chem. 276(28), 26365-26373 (2001
18. Cheng HT, Chen JY, Huang YC et al. Functional role of VDR in the activation of p27Kip1 by the VDR/Sp1 complex. J. Cell Biochem. 98(6), 1450-1456 (2006
19. Hershberger PA, Modzelewski RA, Shurin ZR et al. 1,25- dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res. 59(11), 2644-2649 (1999 (Pubitemid 29269112)
20. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res. 57(17), 3759-3764 (1997 (Pubitemid 27381220)
21. Trump DL, Hershberger PA, Bernardi RJ et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J. Steroid Biochem. Mol. Biol. 89-90(1-5), 519-526 (2004 (Pubitemid 38844341)
22. Bernardi RJ, Trump DL, Yu WD, McGuire TF, Hershberger PA, Johnson CS. Combination of 1a,25- dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin. Cancer Res. 7(12), 4164-4173 (2001 (Pubitemid 34044642)
23. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 10(2), 142-153 (1996 (Pubitemid 26049905)
24. Jemal A, Thun MJ, Ries LA et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J. Natl Cancer Inst. 100(23), 1672-1694 (2008
25. Kilkkinen A, Knekt P, Heliövaara M et al. Vitamin D status and the risk of lung cancer: a cohort study in Finland. Cancer Epidemiol. Biomarkers Prev. 17(11), 3274-3278 (2008
26. Zhou W, Heist RS, Liu G et al. Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol. Biomarkers Prev. 15(11), 2239-2245 (2006 (Pubitemid 44877051)
27. Higashimoto Y, Ohata M, Nishio K et al. 1a, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res. 16(5A), 2653-2659 (1996 (Pubitemid 26388231)
28. McElwain MC, Dettlebach MA, Modzelewski RA et al. Antiproliferative effects in vitro and invivo of 1, 25- dihydroxyvitamin D3 and a vitamin D3 analogue in squamous cell carcinoma model system. Mol. Cell. Differ. 3, 31-50 (1995
29. Young MR, Ihm J, Lozano Y, Wright MA, Prechel MM. Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol. Immunother. 41(1), 37-45 (1995
30. Nakagawa K, Sasaki Y, Kato S, Kubodera N, Okano T. 22-Oxa-1a,25- dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 26(6), 1044-1054 (2005 (Pubitemid 41214297)
31. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J. Immunol. 181(10), 7090-7099 (2008
32. Srinivasan M, Parwani AV, Hershberger PA, Lenzner DE, Weissfeld JL. Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J. Steroid Biochem. Mol. Biol. 123(1-2), 30-36 (2011
33. Menezes RJ, Cheney RT, Husain A et al. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol. Biomarkers Prev. 17(5), 1104-1110 (2008
34. Chen G, Kim SH, King AN et al. CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin. Cancer Res. 17(4), 817-826 (2010
35. Parise RA, Egorin MJ, Kanterewicz B et al. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int. J. Cancer 119(8), 1819-1828 (2006). (Pubitemid 44356838)
36. Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother. Pharmacol. 57(2), 234-240 (2006 (Pubitemid 41779843)
37. Kim B, Lee HJ, Choi HY et al. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res. 67(15), 7431-7438 (2007 (Pubitemid 47206573)
38. Zitzelsberger H, Engert D, Walch A et al. Chromosomal changes during development and progression of prostate adenocarcinomas. Br. J. Cancer 84(2), 202-208 (2001 (Pubitemid 32113447)
39. Fridlyand J, Snijders AM, Ylstra B et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 6, 96 (2006
40. Diep CB, Kleivi K, Ribeiro FR, Teixeira MR, Lindgjaerde OC, Lothe RA. The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosomes Cancer 45(1), 31-41 (2006). (Pubitemid 46930859)